Federal Government Announces Exploratory/Developmental Bioengineering Research Grant (R21 Clinical Trial Not Allowed) Funding

U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute announces the availability of funding for implementation of the Exploratory/Developmental Bioengineering Research Grant (R21 Clinical Trial Not Allowed). The purpose of this grant is to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. Contractors should refer to Section VII, Agency Contacts, in the RFP for information regarding each Institute's grants management contact for this program . . .

Restricted Content

You must be a member to view this resource.

Federal Government Announces Exploratory/Developmental Bioengineering Research Grant (R21 Clinical Trial Not Allowed) Funding

Site Footer